Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

760
(from Reference Citation Analysis)

Article PDFs (14)

Cited by > 0 (425)

Searched Name

Yuka Komatsu

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Number	Citation Analysis
51	Dazai M, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Nakano S, Ishiguro A, Tateyama M, Sato A, Kobayashi Y, Nakamura M, Okuda H, Takahashi Y, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y, Komatsu Y. HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
52	Nakamura M, Muranaka T, Yagisawa M, Kawamoto Y, Yuki S, Ishiguro A, Dazai M, Sogabe S, Harada K, Kobayashi Y, Miyagishima T, Okamura N, Tsuji Y, Terae S, Ono K, Komatsu Y. A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
53	Iwanaga I, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Ito Y, Taketomi A, Hirano S, Sakamoto N, Komatsu Y. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
54	Ishiguro A, Yuki S, Nakano S, Kawamoto Y, Sawada K, Tsuji Y, Honda T, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
55	Yoshikawa A, Kawamoto Y, Yuki S, Nakano S, Sawada K, Muranaka T, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Saiki T, Ishiguro A, Saito R, Ehira N, Iwanaga I, Hatanaka K, Abe N, Sakamoto N, Sakata Y, Komatsu Y. HGCSG1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
56	Nakamura M, Yagisawa M, Saiki T, Ishiguro A, Sawada K, Yuki S, Sasaki T, Ando T, Ohori H, Kotaka M, Muto O, Shindo Y, Nakashima K, Hosokawa A, Doi A, Izawa N, Sunakawa Y, Satoh A, Ono K, Komatsu Y. A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
57	Suzuki K, Yuki S, Nakano S, Kawamoto Y, Nakatsumi H, Hatanaka K, Ando T, Furukawa K, Ishiguro A, Ohta T, Eto K, Nakajima J, Nakamura M, Sogabe S, Kato K, Tateyama M, Kato S, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
58	Sawada K, Komatsu Y, Muranaka T, Nakano S, Kawamoto Y, Nakatsumi H, Yuki S, Dazai M, Saiki T, Ishiguro A, Tateyama M, Ono K, Ohnishi S, Sakamoto N. The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy (MEC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
59	Kagawa Y, Satake H, Kato T, Oba K, Yasui H, Nakamura M, Watanabe T, Hirata K, Muro K, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Kotaka M, Tsuji A, Kakeji Y, Oki E, Nagata N, Junichi S. Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
60	Tsuji Y, Yuki S, Sawada K, Muranaka T, Kobayashi Y, Okuda H, Ogawa K, Minami S, Honda T, Dazai M, Kato T, Sasaki T, Shindo Y, Ota S, Sato A, Ueda A, Saitoh S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
61	Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Chand V, Watanabe M. Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
62	Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Sakamoto S, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T. BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
63	Nakamura M, Takashima A, Denda T, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Ohori H, Sekikawa T, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Ishioka C, Shimada K, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T. Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
64	Kawakami T, Yamazaki K, Oki E, Shimokawa M, Takahashi N, Yokota M, Tokunaga S, Esaki T, Gamoh M, Maeda A, Tsuji Y, Sakai A, Hatanaka K, Shimada Y, Shiozawa M, Komatsu Y, Okuda H, Ohue M, Maehara Y. Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
65	Kotani D, Bando H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Sakamoto S, Iida S, Matsuda S, Yonemura M, Fuse N, Sato A, Fujii S, Ebi H, Ohtsu A, Yoshino T. BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.152] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
66	Morizane C, Komatsu Y, Takahashi H, Ueno M, Furuse J, Kudo T, Itoh S, Shimizu S, Nakamura K, Kamata K, Ohtsubo K, Mizukami T, Kagawa Y, Nomura S, Kuwata T, Fujii S, Okamoto W, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
67	Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Tokunaga S, Emi Y, Makiyama A, Kawamoto Y, Komatsu Y, Shimokawa M, Saeki H, Oki E, Baba H, Maehara Y. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
68	Hiraya D, Sato A, Hoshi T, Watabe H, Yoshida K, Komatsu Y, Kuroki K, Yamasaki H, Sekiguchi Y, Takeyasu N, Nogami A, Aonuma K. P6601Association of coronary artery disease and revascularization with recurrence of atrial fibrillation after catheter ablation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
69	Hanaki Y, Machino T, Tsumagari Y, Komatsu Y, Yamagami A, Machino T, Yamasaki H, Sekiguchi Y, Nogami A, Aonuma K. P1928Impact of sinus rhythm restoration prior to catheter ablation for long-standing persistent atrial fibrillation on procedural outcome: a comparison by propensity score analysis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
70	Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
71	Shindo Y, Yuki S, Yagisawa M, Kawamoto Y, Tsuji Y, Hatanaka K, Kobayashi Y, Kajiura S, Ishiguro A, Honda T, Dazai M, Eto K, Nakamura M, Koike M, Ota S, Sato A, Kato K, Ueda A, Fukunaga A, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
72	Nakamura M, Komatsu Y, Muranaka T, Yagisawa M, Kawamoto Y, Nakatsumi H, Yuki S, Saiki T, Ishiguro A, Tateyama M, Kobayashi Y, Miyagishima T, Takahata T, Sato A, Dazai M, Okuda H, Fujikawa K, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y. HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
73	Yamazaki K, Yasui H, Yamaguchi K, Kagawa Y, Kuboki Y, Yoshino T, Gamoh M, Komatsu Y, Satake H, Goto M, Tanioka H, Oki E, Kotaka M, Makiyama A, Denda T, Soeda J, Shibya K, Iwata M, Oba K, Kato T. A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
74	Ishiguro A, Kawamoto Y, Yuki S, Nakano S, Yagisawa M, Sawada K, Muranaka T, Hayashi H, Nakatsumi H, Saiki T, Harada K, Kobayashi Y, Iwanaga I, Hatanaka K, Sakata Y, Komatsu Y. HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
75	Yoshino T, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
76	Bando H, Tsukada Y, Inamori K, Fukuoka S, Sasaki T, Nishizawa Y, Wakabayashi M, Kojima M, Togashi Y, Yuki S, Komatsu Y, Homma S, Hatanaka Y, Matsuno Y, Uemura M, Kato T, Sato A, Nishikawa H, Ito M, Yoshino T. VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.227] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
77	Kato T, Satake H, Oba K, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Hirata K, Muro K, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Kotaka M, Tsuji A, Kakeji Y, Oki E, Nagata N, Sakamoto J. Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
78	Muranaka T, Komatsu Y, Ohnishi S, Yagisawa M, Sawada K, Kawamoto Y, Nakatsumi H, Yuki S, Dazai M, Saiki T, Ishiguro A, Tateyama M, Ono K, Sakamoto N. The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
79	Yuki S, Komatsu Y, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Shinohara T, Miyashita K, Ito Y, Taketomi A, Hirano S, Sakamoto N. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
80	Honda T, Yuki S, Muranaka T, Nakatsumi H, Tsuji Y, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Ishiguro A, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Onodera K, Eto K, Tateyama M, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
81	Tabeta K, Hosojima M, Nakajima M, Miyauchi S, Miyazawa H, Takahashi N, Matsuda Y, Sugita N, Komatsu Y, Sato K, Ishikawa T, Akiishi K, Yamazaki K, Kato K, Saito A, Yoshie H. Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey. J Periodontal Res 2018. [DOI: 10.1111/jre.12533] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
82	Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Aonuma A, Abe N, Sato A, Nakatsumi H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Sakamoto N, Komatsu Y. HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
83	Yoshita H, Yuki S, Yagisawa M, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Dazai M, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Sakata Y, Komatsu Y. First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
84	Yamazaki K, Satoh T, Komatsu Y, Taguchi T, Sunaga Y, Yoshino T. Impact of KRAS mutational status and primary tumor location on the efficacy of aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer: An exploratory analysis in a phase II study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
85	Yuki M, Miyake A, Nakatsumi H, Hirayama K, Ishioka A, Yamashita H, Komatsu Y. Family exposure to cyclophosphamide during outpatient treatment. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx668.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
86	Miyagishima T, Yuki S, Muranaka T, Tsuji Y, Ota Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Nakamura M, Ohta T, Honda T, Ishiguro A, Muto O, Kato S, Sato A, Abe M, Sakata Y, Komatsu Y. Analysis of tumor location: A retrospective trial for evaluating the safety and efficacy of regorafenib for patients with metastatic colorectal cancer: HGCSG1401. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
87	Kang YK, Kato K, Chung H, Minashi K, Lee KW, Cho H, Kang W, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Boku N, Chen LT. Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
88	Kurokawa Y, Doi T, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Okubo S, Nishida T. Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
89	Ishiguro A, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Kusumi T, Iwanaga I, Miyagishima T, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Ito Y, Komatsu Y. North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003): Analysis of tumor location. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
90	Komatsu Y, Takashima A, Denda T, Gamoh M, Iwanaga I, Shimodaira H, Nakamura M, Yamaguchi T, Takahashi H, Kobayashi K, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Sato A, Yuki S, Morita S, Takahashi S, Shimada K. Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
91	Takayoshi K, Okamoto W, Hironaka S, Honma Y, Ebi H, Nakanishi R, Kajiwara T, Kudo T, Tamura T, Komatsu Y, Hara H, Naruge D, Moriwaki T, Miki I, Sudo T, Nomura S, Fujii S, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
92	Nakamura Y, Okamoto W, Sawada K, Komatsu Y, Kato K, Taniguchi H, Kato T, Nishina T, Esaki T, Nomura H, Fukutani M, Fukui M, Hasegawa H, Yonemura M, Fuse N, Sato A, Fujii S, Ohtsu A, Yoshino T. TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.137] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
93	Yagisawa M, Nakamura M, Muranaka T, Kawamoto Y, Nakatsumi H, Yuki S, Sasaki T, Meguro T, Dazai M, Ishiguro A, Eto K, Harada K, Kobayashi Y, Miyagishima T, Iwanaga I, Uebayashi M, Hatanaka K, Sakamoto N, Sakata Y, Komatsu Y. Multicenter prospective cohort study to evaluate of eye disorder induced by chemotherapy including S-1 (EyeDropS study/HGCSG1604). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
94	Yamazaki K, Kuboki Y, Shinozaki E, Hara H, Komatsu Y, Nishina T, Yamaguchi K, Yuki S, Bando H, Asayama M, Tsushima T, Hamauchi S, Nakatsumi H, Kajiwara T, Wakabayashi M, Nomura S, Sato A, Doi T, Ohtsu A, Yoshino T. A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
95	Yuki S, Komatsu Y, Yagisawa M, Tsuji Y, Harada K, Hatanaka K, Okuda H, Hosokawa A, Ogawa K, Furukawa K, Minami S, Ishiguro A, Honda T, Ohta T, Dazai M, Eto K, Sasaki T, Nakajima J, Sakamoto N, Sakata Y. A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
96	Musha A, Saitoh JI, Shirai K, Kubota Y, Shimada H, Abe T, Komatsu Y, Komatsu S, Ohno T, Nakano T, Yokoo S. Customized mouthpieces designed to reduce tongue mucositis in carbon-ion radiotherapy for tumors of the nasal and paranasal sinuses. PHYSICS & IMAGING IN RADIATION ONCOLOGY 2017. [DOI: 10.1016/j.phro.2017.07.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
97	Igarashi M, Nogami A, Sekiguchi Y, Nitta J, Sakamoto N, Kurosaki K, Takahashi Y, Komatsu Y, Machino T, Kuroki K, Yamasaki H, Iesaka Y, Aonuma K. P1628Acute and long-term results of bipolar radiofrequency catheter ablation of refractory ventricular arrhythmias with deep intramural origins. Europace 2017. [DOI: 10.1093/ehjci/eux158.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
98	Yamasaki H, Yamagami F, Shinoda Y, Adachi TORU, Hattori A, Komatsu Y, Masuda K, Machino T, Kuroki K, Sekiguchi Y, Yamaguchi I, Nogami A, Aonuma K. P870Pulmonary vein isolation using a novel radiofrequency hot-balloon catheter in patients with paroxysmal atrial fibrillation: initial results using an antrum ablation technique. Europace 2017. [DOI: 10.1093/ehjci/eux151.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
99	Yoshizawa R, Kuroki K, Hashimoto N, Yamagami F, Shinoda Y, Hattori A, Masuda K, Adachi T, Komatsu Y, Machino T, Yamasaki H, Sekiguchi Y, Nogami A, Yamaguchi I, Aonuma K. P1441The characteristics of superior vena cava isolation, which is useful to avoid procedural complications: the findings obtained from high- resolution substrate mapping. Europace 2017. [DOI: 10.1093/ehjci/eux158.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
100	Kitanohara M, Yamamoto T, Masunaga S, Ohishi M, Komatsu Y, Nagase M. Effect of porcine placental extract on the mild menopausal symptoms of climacteric women. Climacteric 2017;20:144-150. [PMID: 28112981 DOI: 10.1080/13697137.2017.1279140] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Abstract OBJECTIVES This study assessed the effects of oral porcine placental extract (PPE) on the mild menopausal symptoms of climacteric women. METHODS In this 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 50 climacteric Japanese women were randomized 1 : 1 to oral PPE (300 mg/day) or placebo. Menopausal symptoms were evaluated by using the Simplified Menopausal Index (SMI), as were serum estradiol (E2) and follicle stimulating hormone (FSH) levels. Blood biochemical and cellular and urinary tests were done to evaluate safety aspects of repeated oral administration of PPE. RESULTS The total SMI score of the PPE group was significantly more improved after 12 weeks than that of the placebo group (p = 0.031). This score and three subscores (vasomotor, psychological, and somatic symptoms) were significantly improved at 8 and/or 12 weeks compared with the initial values in the PPE group (p < 0.05). E2 and FSH levels were not improved in either group. No adverse events were observed. CONCLUSIONS Oral PPE at 300 mg/day improved the mild menopausal symptoms of climacteric women. Since oral PPE did not improve serum E2 and FSH levels, PPE is thought not to ameliorate hormonal balance itself but to improve subjective feelings of climacteric women. Collapse Key Words Menopausal symptoms Simplified Menopausal Index climacteric women dietary supplement porcine placental extract Collapse MESH Headings Collapse Grants Collapse